Health-related quality of life and economic burden in patients with restless legs syndrome

References

• Ekbom KA. Restless legs. Acta Med. Scand.158, S1–S123 (1945).
   Google Scholar
• Oertel WH, Trenkwalder C, Zucconi M et al. State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome. Mov. Disord. (2007) (Epub ahead of print).
   Google Scholar
• Kushida CA. Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome. Am. J. Med.120(1 Suppl. 1), S4–S12 (2007).
   PubMed Web of Science ®Google Scholar
• Mrowka M, Ray Chaudhuri K, Odin P. Pathophysiology of restless legs syndrome. In: Restless Legs Syndrome. Ray Chaudhuri K, Odin P, Olanow CW (Eds). Taylor & Francis, London & NY, 37–48 (2004).
   Google Scholar
• Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol.5(10), 878–886 (2006).
   PubMed Web of Science ®Google Scholar
• Ekbom KA. Restless legs syndrome. Neurology10, 868–873 (1960).
   PubMed Web of Science ®Google Scholar
• Oboler SK, Prochazka AV, Meyer TJ. Leg symptoms in outpatient veterans. West J. Med.155(3), 256–259 (1991).
   PubMedGoogle Scholar
• Walters AS, LeBrocq C, Dhar A et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med.4(2), 121–132 (2003).
   PubMed Web of Science ®Google Scholar
• Sevim S, Dogu O, Camdeviren H et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology61(11), 1562–1569 (2003).
   PubMed Web of Science ®Google Scholar
• Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology54(5), 1064–1068 (2000).
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med.4(2), 101–119 (2003).
   PubMed Web of Science ®Google Scholar
• Hui DS, Wong TY, Li TS et al. Prevalence of sleep disturbances in Chinese patients with end stage renal failure on maintenance hemodialysis. Med. Sci. Monit.8(5), CR331–CR336 (2002).
   PubMedGoogle Scholar
• The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs. Sleep Med.4, 121–132 (2003).
   PubMed Web of Science ®Google Scholar
• Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C. Severity rating of Restless Legs Syndrome: review of ten years experience with the RLS-6 scales in clinical trials. Sleep26, A342 (2003).
   Google Scholar
• Kohnen R, Allen RP, Benes H et al. Assessment of restless legs syndrome – methodological approaches for use in practice and clinical trials. Mov. Disord. (2007).
   Google Scholar
• Allen RP, Earley CJ. Validation of the John Hopkins Restless Legs Severity Scale (JHRLSS). Sleep Med.3, 239–242 (2001).
   Web of Science ®Google Scholar
• Trenkwalder C, Stiasny K, Pollmacher T et al.L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep18(8), 681–688 (1995).
   PubMed Web of Science ®Google Scholar
• Collado-Seidel V, Kazenwadel J, Wetter TC et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology52(2), 285–290 (1999).
   PubMed Web of Science ®Google Scholar
• Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep22(8), 1073–1081 (1999).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Bodenschatz R et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology67(6), 1040–1046 (2006).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. (2007) (Epub ahead of print).
   Google Scholar
• Oertel WH, Stiasny-Kolster K, Bergtholdt B et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov. Disord.22(2), 213–219 (2007).
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov. Disord.21(9), 1404–1410 (2006).
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Garcia-Borreguero D, Montagna P et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J. Neurol. Neurosurg. Psychiatry75(1), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Möller C, Körner Y, Cassel W et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med.7, 333–339 (2006).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry77, 918–926 (2006).
   PubMed Web of Science ®Google Scholar
• Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D – a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry69(1), 67–73 (2000).
   PubMed Web of Science ®Google Scholar
• Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke37(1), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care30(6), 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy16(3), 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Bullinger M, Kirchberger I, Ware J. Der deutsche SF-36 Health Survey. Übersetzung und psychometrische Testung eines krankheitsübergreifenden Instruments zur Erfassung der gesundheitsbezogenen Lebensqualität. Gesundheitswesen3, 21–36 (1995).
   Google Scholar
• Moore AP, Lloyd A, Scott DA, Connolly M, Dixon S. The cost-effectiveness of treating patients with restless legs syndrome (RLS) using ropinirole. Value Health7(6), 791 (2004).
   Google Scholar
• Saletu M, Anderer P, Hogl B et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J. Neural Transm.110(6), 611–626 (2003).
   PubMed Web of Science ®Google Scholar
• Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur. Arch. Psychiatry Clin. Neurosci.252(4), 185–194 (2002).
   PubMed Web of Science ®Google Scholar
• Saletu M, Anderer P, Saletu B, Lindeck-Pozza L, Hauer C, Saletu-Zyhlarz G. EEG mapping in patients with restless legs syndrome as compared with normal controls. Psychiatry Res.115(1–2), 49–61 (2002).
   Google Scholar
• Mezzich JE, Ruiperez MA, Perez C, Yoon G, Liu J, Mahmud S. The Spanish version of the quality of life index: presentation and validation. J. Nerv. Ment. Dis.188(5), 301–305 (2000).
   PubMed Web of Science ®Google Scholar
• Abetz L, Arbuckle R, Allen RP, Mavraki E, Kirsch J. The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health Qual. Life Outcomes3, 79 (2005).
   PubMedGoogle Scholar
• Atkinson MJ, Allen RP, DuChane J, Murray C, Kushida C, Roth T. Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual. Life Res.13(3), 679–693 (2004).
   Google Scholar
• Kohnen R, Benes H, Kurella B. Development of the disease-specific restless legs syndrome quality of life (RLS-QoL) questionnaire. Mov. Disord.17(Suppl. 5), P743 (2002).
   Google Scholar
• Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health8(2), 157–167 (2005).
   PubMed Web of Science ®Google Scholar
• Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov. Disord.19(12), 1414–1423 (2004).
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Grote L et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. Mov. Disord.22(5), 696–703 (2007).
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Sethi KD, Kushida CA et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology67(6), 1034–1039 (2006).
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov. Disord.21(10), 1627–1635 (2006).
   PubMed Web of Science ®Google Scholar
• Abetz L, Allen R, Follet A et al. Evaluating the quality of life of patients with restless legs syndrome. Clin. Ther.26(6), 925–935 (2004).
   PubMed Web of Science ®Google Scholar
• Allen RP, Walters AS, Montplaisir J et al. Restless legs syndrome prevalence and impact: REST general population study. Arch. Intern. Med.165(11), 1286–1292 (2005).
   PubMed Web of Science ®Google Scholar
• Gerhard R, Bosse A, Uzun D, Orth M, Kotterba S. Quality of life in restless legs syndrome. Influence of daytime sleepiness and fatigue. Med. Klin. (Munich)100(11), 704–709 (2005).
   Google Scholar
• McCrink L, Allen RP, Wolowacz S, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med.8(1), 73–83 (2007).
   PubMedGoogle Scholar
• Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med.5(5), 485–488 (2004).
   PubMed Web of Science ®Google Scholar
• Maurel F, Girard B, Crochard A, Henri M, El Hasnaoui A, Le Pen C. Profile of patients suffering from restless legs syndrome and estimation of their annual cost in an amulatory care setting, in France. Value Health7(1), 658–805 (2004).
   Google Scholar
• Curtice TG, Long SR, Baser O, Montejano LB, Lobo F. Economic burden of restless legs syndrome in a privately-insured population. Value Health9(3), A24–A174 (2006).
   Google Scholar
• Douzinas N, Connolly MP, Kirsch J, Morris S. Establishing the indiret costs of RLS based on severity using the International restless legs severity rating scale (IRLS) and the productivity and activity impairment. Eur. J. Neurol.12(s2), 37–300 (2005).
   Google Scholar
• Lees LM, Roberts RG, Tabberer TM, Björkman J, Ulfberg J, Finnern H. Cost–effectiveness of treating restless legs patients with pramipexole compared to no treatment in Sweden. Value Health9(6), A208–A393 (2006).
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J.146(4), 473–481 (1992).
   PubMed Web of Science ®Google Scholar
• Beard AJ. Examination of the cost–effectiveness of dopamine agonists for the treatment of restless legs syndrome. Value Health9(3), A81 (2006).
   Google Scholar
• Bergmann L, Behrens M, Dietl M, Banik N. Prevalence and characterization of the restless legs syndrome in the offices of German GPs. MMW Fortschr. Med.148(41), 44 (2006).
   Google Scholar
• Perez-Romero T, Comas-Fuentes A, Deban-Fernandez M, Gonzalez-Nuevo Quinones JP, Maujo-Fernandez J. Prevalence of restless legs syndrome at the office in primary health care. Rev. Neurol.44(11), 647–651 (2007).
   Google Scholar
• Castillo PR, Kaplan J, Lin SC, Fredrickson PA, Mahowald MW. Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin. Proc.81(10), 1345–1347 (2006).
   Google Scholar
• Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L. Restless legs syndrome: prevalence and impact in children and adolescents – the Peds REST study. Pediatrics120(2), 253–266 (2007).
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med.7(7), 545–552 (2006).
   PubMed Web of Science ®Google Scholar
• Phillips B, Hening W, Britz P, Mannino D. Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest129(1), 76–80 (2006).
   PubMed Web of Science ®Google Scholar
• Vogl FD, Pichler I, Adel S et al. Restless legs syndrome: epidemiological and clinicogenetic study in a South Tyrolean population isolate. Mov. Disord.21(8), 1189–1195 (2006).
   PubMed Web of Science ®Google Scholar
• Hersberger KE, Renggli VP, Nirkko AC, Mathis J, Schwegler K, Bloch KE. Screening for sleep disorders in community pharmacies – evaluation of a campaign in Switzerland. J. Clin. Pharm. Ther.31(1), 35–41 (2006).
   PubMed Web of Science ®Google Scholar
• Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology65(2), 239–246 (2005).
   PubMed Web of Science ®Google Scholar
• Kim J, Choi C, Shin K et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population: the Korean Health and Genome Study. Psychiatry Clin. Neurosci.59(3), 350–353 (2005).
   PubMed Web of Science ®Google Scholar
• Bjorvatn B, Leissner L, Ulfberg J et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med.6(4), 307–312 (2005).
   PubMed Web of Science ®Google Scholar
• Hogl B, Kiechl S, Willeit J et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology64(11), 1920–1924 (2005).
   PubMed Web of Science ®Google Scholar
• Rijsman R, Neven AK, Graffelman W, Kemp B, de Weerd A. Epidemiology of restless legs in The Netherlands. Eur. J. Neurol.11(9), 607–611 (2004).
   PubMed Web of Science ®Google Scholar
• Van De Vijver DA, Walley T, Petri H. Epidemiology of restless legs syndrome as diagnosed in UK primary care. Sleep Med.5(5), 435–440 (2004).
   PubMedGoogle Scholar
• Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK. Restless legs syndrome in an Asian population: A study in Singapore. Mov. Disord.16(3), 577–579 (2001).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ohida T, Sone T et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep26(6), 673–677 (2003).
   PubMed Web of Science ®Google Scholar
• Nichols DA, Allen RP, Grauke JH et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch. Intern. Med.163(19), 2323–2329 (2003).
   PubMed Web of Science ®Google Scholar
• Schmitt BE, Gugger M, Augustiny K, Bassetti C, Radanov BP. Prevalence of sleep disorders in an employed Swiss population: results of a questionnaire survey. Schweiz Med. Wochenschr.130(21), 772–778 (2000).
   PubMedGoogle Scholar
• Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch. Intern. Med.160(14), 2137–2141 (2000).
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J. Psychosom. Res.53(1), 547–554 (2002).
   PubMed Web of Science ®Google Scholar
• Thorpy MJ. Classification of sleep disorders. J. Clin. Neurophysiol.7(1), 67–81 (1990).
   Google Scholar
• Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep17(8), 739–743 (1994).
   PubMed Web of Science ®Google Scholar
• Machtey I. Epidemiology of restless legs syndrome. Arch. Intern. Med.161(3), 483–484 (2001).
   Google Scholar
• Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov. Disord.16(6), 1159–1163 (2001).
   PubMed Web of Science ®Google Scholar
• Kushida C, Martin M, Nikam P et al. Burden of restless legs syndrome on health-related quality of life. Qual. Life Res.16(4), 617–624 (2007).
   PubMed Web of Science ®Google Scholar
• Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch. Intern. Med.164(2), 196–202 (2004).
   PubMed Web of Science ®Google Scholar
• Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med.5(3), 237–246 (2004).
   PubMed Web of Science ®Google Scholar
• Saletu B, Anderer P, Saletu M, Hauer C, Lindeck-Pozza L, Saletu-Zyhlarz G. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med.3(Suppl.), S35–S42 (2002).
   PubMed Web of Science ®Google Scholar
• Stiasny K, Wetter TC, Winkelmann J et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology56(10), 1399–1402 (2001).
   PubMed Web of Science ®Google Scholar
• Wetter TC, Stiasny K, Winkelmann J et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology52(5), 944–950 (1999).
   PubMed Web of Science ®Google Scholar